Abstract The adenosine A 2B receptor is the least well characterized of the four adenosine subtypes due to the lack of potent and selective agonists and antagonists. Despite the widespread distribution of A 2B receptor mRNA, little information is available with regard to their function.
7-(2-phenylethyl)-2-(2-furyl)-pyrazolo [4,3- [2, 3] . It has been suggested that adenosine receptors act as "sensors" and that extracellular adenosine acts as a "reporter" of metabolic changes in the local tissue environment [4, 5] . Therefore, under normal conditions adenosine, which is continuously produced intracellularly and extracellularly and maintained at low intracellular levels (about 100 nM) by adenosine kinase and adenosine deaminase, interacts with the high-affinity A 1 and A 2A receptor subtypes. In hypoxic, ischaemic or inflamed conditions the intracellular production of adenosine is increased to very high micromolar concentrations and transported across cell membranes by specific agents finally leading to the stepwise activation of all adenosine receptors, including the low-affinity A 2B and A 3 subtypes [6] . Whilst for A 1 , A 2A and A 3 adenosine subtypes good agonists and antagonists have been synthesized allowing a plethora of binding and functional studies, no high-affinity analogues have been identified for the A 2B receptors until a couple of years ago, and neither high-affinity nor selective antagonists had been introduced until 2001 [3, 7, 8] . Therefore studies concerning A 2B receptors rely on mRNA distribution, cloning and functional assays performed with not very selective molecules [9] . However considering the potential therapeutic applications of A 2B ligands, many efforts have been made in the last few years to search for potent and selective antagonists versus this receptor subtype [10] and the recent discovery of novel radiolabelled A 2B antagonists will be useful to the scientific community for the exploration and characterization of the pathophysiological role of A 2B receptors.
A 2B adenosine receptors
A 2B receptors were distinguished from A 2A in 1983 [11] due to the high and low affinity of adenosine in the stimulation of cAMP levels in rat striatum and were cloned for the first time in 1992 from human hippocampus [12] and rat brain [13, 14] and subsequently from mouse bone marrow-derived mast cells [15] . The distribution of A 2B receptors has been detected on practically every cell in different species and relies on the reverse transcription polymerase chain reaction technique. A 2B messenger RNA has been found at low levels in all rat brain regions evaluated, aorta, stomach, testis, skeletal muscle, jejunum, kidney, heart, skin, spleen and liver whilst high levels have been detected in the proximal colon [6] . A 2B are coupled to different signalling pathways such as stimulation of adenylate cyclase through G s proteins and accumulation of intracellular calcium. This pathway is related to different mechanisms such as potentiation of a P-type calcium current in hippocampal neurons [16] , activation of a calcium channel, G s protein-coupled, in human erythroleukemia cells [17] or involvement of phospholipase C in HMC1 cells [18] . More recently, it has also been suggested that they are involved in activation of extracellular regulated kinases 1/2 (ERK1/2) at physiologically normal concentrations [19, 20] . Functional studies have suggested the presence of A 2B receptors in airway smooth muscle, fibroblasts, vasculature, mast cells, macrophages, endothelium, haematopoietic cells and intestinal epithelial cells. In particular, they have been reported to be involved in stimulation of cell proliferation, differentiation and migration of retinal endothelial cells, where A 2B antagonists may offer a way to inhibit retinal angiogenesis and provide a novel therapeutic approach for treatment of diseases associated with aberrant neovascularization, such as diabetic retinopathy [21, 22] . In macrophages it has been reported that their up-regulation induced by interferon gamma (IFN-γ) would lead to the cAMP-mediated down-regulation of MHC class II molecules and other macrophage activities. This may constitute an important mechanism of cell deactivation at the inflammatory foci [23] . In human mast cells 5 0 -N-ethyl-carboxamidoadenosine (NECA) induced interleukin-8 secretion through the involvement of p38 mitogen-activated protein kinase and extracellular signal-regulated protein kinase kinase and this effect was blocked by 3-isobutyl-8-pyrrolidinoxanthine (IPDX) suggesting a basis for the development of new antiasthmatic drugs [24] [25] [26] . The recent discovery that A 2B receptors are also functionally active on human airway smooth muscle cells to enhance cytokine and chemokine release [27] and on lung fibroblasts where they promote differentiation to a myofibroblast phenotype [28] supports the view that this subtype may be involved in airway wall remodelling and in asthma [29] . Interestingly a role of A 2B receptors has also been observed in the analgesic effects of caffeine in an acute animal model of nociception, suggesting that specific A 2B antagonists might be valuable adjuvant drugs for opioid analgesia with minimal side effects [30] . The high expression of A 2B receptors in different parts of the intestinal tract raised great interest in defining their function. It has been suggested that they play a role in epithelial secretion with potential relevance to diarrhoeal processes [31] . Moreover A 2B receptors are involved in coronary flow regulation [32] , stimulation of proangiogenic factors [33] [34] [35] and they have been proposed as targets to control cell growth and proliferation in a human breast cancer cell line [36] . All together these effects suggest a possible role of the A 2B subtype in the modulation of inflammatory processes involved in asthma, tumour growth, tissue injury, ischaemia and pain [37, 38] . Targeting of the A 2B receptor protein to specific cells or tissues is crucial in order to understand their role in pathophysiological conditions. Unfortunately, the lack of selective agonists and antagonists has hampered the pharmacological characterization of this receptor system. Only recently Ijzerman's group developed new, high-potency A 2B agonists with an improved selectivity profile compared to the reference agonist NECA, and the discovery of the first A 2B partial agonist that appears very promising for future functional studies [39] . The characterization of A 2B receptors, therefore, often was based on the lack of effectiveness of compounds that are potent and selective agonists of other receptor subtypes. The agonist CGS 21680, for example, has been useful in differentiating between A 2A and A 2B receptors [40] . However, pharmacological characterization of receptors based on apparent agonist potencies is far from ideal, because it depends not only on agonist binding to the receptor but also on multiple processes involved in signal transduction. Recently, based on functional assays using novel A 2B selective antagonists, significant progress has been made in the understanding of the molecular pharmacology and physiology of A 2B adenosine receptors and novel progress in this field is supposed to be increased by the introduction of the tritiated radiolabelled form of some new A 2B [44] . In addition, since these ligands are non-selective their utility in native systems is hampered as many tissues and cell lines express several adenosine subtypes.
Xanthines, including the natural derivatives theophylline and caffeine, are the natural non-selective antagonists of adenosine and they are able to bind to all four adenosine receptor subtypes A 1 , A 2A , A 2B and A 3 [6] . Therefore the xanthine core has been maintained and modified in order to develop new A 2B drugs. This approach led to the discovery of new molecules introduced as high-affinity radioligands for A 2B 3 H]MRS 1754 was consistent with the structure-activity relationship for agonists and antagonists at A 2B receptors. In spite of the high affinity and selectivity, this radioligand has not been used in cells and tissues endogenously expressing A 2B receptors.
Some years later a pyrrolopyrimidine compound [ 3 H] OSIP339391 was introduced as a high-affinity and selective radioligand to A 2B receptors [42] . OSIP339391 had a selectivity of greater than 70-fold for A 2B receptors over other human adenosine receptor subtypes. Using membranes from HEK 293 cells expressing the human recombinant A 2B receptor, [ 3 H]OSIP339391 was characterized in kinetic, saturation and competition binding experiments. From the association and dissociation rate studies, the affinity was 0.41 nM and in close agreement with that found in saturation binding experiments (0.17 nM). In competition binding studies of [ 3 H]OSIP339391, the affinity of a range of agonists and antagonists was consistent with previously reported data. However, also in this case, its suitability to label endogenous A 2B receptors cannot be assessed due to the lack of binding studies in cells or tissues.
Our research group has identified a series of 8-pyrazole xanthine derivatives as potent and selective human A 2B adenosine antagonists [46] , and a radiolabelled form of one compound of this series, [ 3 H]MRE 2029-F20 [47] , was used as new pharmacological tool to describe the comparison between human recombinant A 2B receptors stably transfected in HEK 293 cells and endogenous receptors present in human neutrophils and lymphocytes [43] . [ 3 H]MRE 2029-F20 showed high affinity and selectivity for hA 2B versus hA 1 2B receptors was consistent with that typically found for interactions with the A 2B subtype and was also similar in peripheral blood cells. NECA stimulated cAMP accumulation in both hA 2B HEK 293 and native cells, whereas phospholipase C activation was observed in recombinant receptors and endogenous subtypes expressed in neutrophils but not in lymphocytes. MRE 2029-F20 was revealed to be a potent antagonist in counteracting the agonist effect in both signal transduction pathways. In conclusion, [ 3 H] MRE 2029-F20 was revealed to be a selective and highaffinity radioligand for the hA 2B adenosine subtype and may be used to quantify A 2B endogenous receptors such as those present in neutrophils and lymphocytes that represent inflammatory cells potentially involved in the exacerbation of asthma and other inflammatory processes in which A 2B receptors are thought to be involved [29] . This was the first paper reporting both binding and functional studies in recombinant and native receptors. . Moreover, the compounds tested were able to decrease NECA-stimulated and also forskolinstimulated cAMP production, revealing them to be novel antagonists with an inverse agonist activity in recombinant and native human A 2B receptors [48] .
Conclusions
In recent years remarkable attention has been paid to A 2B receptors due to their supposed role in important pathological states such as asthma, diarrhoeal processes, diabetic retinopathy, vasodilation, neoangiogenesis and nociception. For many years their study has been strongly limited by the lack of good and selective pharmacological probes and many efforts have been focused by chemists and biologists on the synthesis and testing of new selective ligands. The data presented in this review clearly underline the significant progress made in the field of A 2B receptor antagonists. Novel high-affinity and selective antagonist radioligands have been recently synthesized that will allow in the future the characterization of this adenosine subtype in endogenous systems (Table 1) . a See ref. [41] b See ref. [42] c See ref. [43] 
